Momenta Pharmaceuticals files lawsuit against Teva

Momenta Pharmaceuticals has filed lawsuit against Teva Pharmaceutical Industries in the US District Court for the District of Massachusetts for infringement of two Momenta Pharma patents. The patents cover the Momenta Pharma’s methods of producing Enoxaparin sodium, which assure that the commercial product meets standards for identity and quality.

Teva said that its generic version of Lovenox, which is manufactured and tested outside of the US, does not infringe either of these patents.

Teva believes that this lawsuit is without merit, and Teva intends to seek reimbursement for all legal fees in fighting these baseless allegations.

Abstracted from LinkedIn prifile: Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Its products include M-Enoxaparin, a technology-enabled generic version of Lovenox that is used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes; and M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis.

Related posts:

  1. Impax Allegra-D 60mg/120mg tablets ANDA gets FDA approval Impax Allegra-D 60mg/120mg tablets ANDA gets FDA approval. Impax Laboratories...
  2. Oligomerix gets SBIR Phase II grant to discover alzheimer’s drugs Oligomerix gets SBIR Phase II grant to discover alzheimer’s drugs...

This entry was posted on Sunday, December 5th, 2010 at 7:52 am and is filed under Generic Drugs. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.